Search

Displaying results 1691 - 1700 of 7452 in total
  1. Drug

    Pacritinib

    go.drugbank.com/drugs/DB11697
    ApprovedInvestigational

    [L40793] JAK2 signaling is important for hematopoiesis and proper immune functioning,[L40754] and while the precise role it plays in the pathogenesis of MF remains unclear, its clear association with MF … Pacritinib is an inhibitor of both wild-type and mutant (V617F) JAK2, as well as FMS-like tyrosine kinase 3 (FLT3), which was granted accelerated approval by the FDA in February 2022 for the treatment

  2. Drug

    L-Glutamine

    go.drugbank.com/drugs/DB00130
    ApprovedInvestigationalNutraceutical

    It is the principal carrier of nitrogen in the body and is an important energy source for many cells. … An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical.

  3. Drug

    Regorafenib

    go.drugbank.com/drugs/DB08896
    ApprovedInvestigational

    It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012.

  4. Drug

    Sodium acetate

    go.drugbank.com/drugs/DB09395
    ApprovedInvestigational

    It can be used also in metabolic acidosis and for urine alkalinization.

    Mixtures: KABIVEN EMULSION FOR INFUSION, GELASPAN SOLUTION FOR INFUSION
  5. Drug

    Donidalorsen

    go.drugbank.com/drugs/DB18751
    ApprovedInvestigational

    [L53788] Donidalorsen was approved by the FDA in August 2025 for prophylactic use to prevent HAE attacks.[L53783,L53788] It is the first RNA-targeted therapy approved for HAE.[L53783]

  6. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    Due to this mutation, all progeny erythrocytes will lack the glycosyl phosphatidylinositol–anchored proteins that normally anchor 2 membrane proteins, CD55 and CD59, that protect blood cells against the … [A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Equine Botulinum Neurotoxin A Immune FAB2

    go.drugbank.com/drugs/DB13900
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A in adults and pediatric patients.

  8. Drug

    Iodide I-123

    go.drugbank.com/drugs/DB09420
    ApprovedInvestigational

    Radioactive I-123 in particular is effective for this use as its half-life of approximately 13.13 h (hours) is ideal for the 24-h (hour) iodine uptake test and it has a reduced radiation burden as compared … Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease.

  9. Drug

    Pegcetacoplan

    go.drugbank.com/drugs/DB16694
    ApprovedInvestigational

    [L34095] In February 2023, pegcetacoplan for intravitreal use was approved by the FDA for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.[L45354] … [A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021.

  10. Drug

    Enalapril

    go.drugbank.com/drugs/DB00584
    ApprovedInvestigationalVet approved

    The active metabolite enalaprilat is also available in oral tablets and intravenous formulations for injection. … It is also found in a combination product containing [hydrochlorothiazide] that is used for the management of hypertension.

    Categories: Antihypertensive Agents Indicated for Hypertension